Myriad Genetics (MYGN) Asset Utilization Ratio (2011 - 2026)

Myriad Genetics has disclosed Asset Utilization Ratio across 16 years of filings, most recently posting 1.2 for Q1 2026.

• In Q1 2026, Asset Utilization Ratio rose 46.93% year-over-year to 1.2; the TTM figure through Mar 2026 stood at 1.2 (up 46.93% YoY), while the FY2025 annual figure was 0.95, up 23.41% from the prior year.
• Asset Utilization Ratio advanced to 1.2 in Q1 2026, from 1.15 in the prior quarter.
• Over the last five years, Asset Utilization Ratio for MYGN reached as high as 1.2 in Q1 2026 and fell as low as 0.53 in Q1 2022.
• The 5-year median for Asset Utilization Ratio is 0.69 (2024), against an average of 0.76.
• Annual changes were most pronounced in 2022 — Asset Utilization Ratio decreased 11.26% — and 2025, when it soared 54.47%.
• A 5-year view of Asset Utilization Ratio shows it stood at 0.56 in 2022, then advanced by 16.59% to 0.66 in 2023, then rose by 21.05% to 0.79 in 2024, then soared by 44.69% to 1.15 in 2025, then gained by 4.51% to 1.2 in 2026.
• According to Business Quant data, Asset Utilization Ratio over the past three periods registered 1.2, 1.15, and 1.17 for Q1 2026, Q4 2025, and Q3 2025 respectively.